Private company

Orphazyme A/S

Orphazyme A/S is a pharmaceutical preparations company.¹

Last updated Oct 21, 2026.

Overview

36.2MRevenue, fiscal 2021²

-626.5MNet income, fiscal 2021²

IndustryPharmaceutical Preparations¹
HeadquartersG7¹
Incorporated inDenmark³
Business addressOle Maaloes Vej 3, Copenhagen N, G7 Dk-2200³
Filer categoryNon-accelerated filer, Emerging growth company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in DKK, the currency the company reports in.

Key numbers, fiscal 2021

-1749.8%Operating margin²

-1731.1%Net margin²

-6708.8%Return on equity²

0.27×Debt to equity²

-602.7M DKKFree cash flow²

Where the money goes

Where each dollar of revenue went, fiscal 2021

Research and development

Research and development95¢330.0M DKK
Interest3¢10.6M DKK
Income tax1¢4.9M DKK

Out of 36.2M DKK in revenue.² The company lost money this year.

Financial statements

Revenue⁴²36.2M DKK in 2021

Operating income⁴²-633.3M DKK in 2021+173% since 2018

Net income⁴²-626.5M DKK in 2021+173% since 2018

Fiscal year	2018	2019	2020	2021
Revenue	0 DKK⁴	0 DKK²	0 DKK²	36.2M DKK²
Research and development				330.0M DKK²
Operating income	-231.7M DKK⁴	-336.0M DKK²	-608.5M DKK²	-633.3M DKK²
Interest				10.6M DKK²
Income before tax				-631.5M DKK²
Income tax				-4.9M DKK²
Net income	-229.6M DKK⁴	-337.5M DKK²	-633.2M DKK²	-626.5M DKK²
Shares (weighted, basic)				34.9M shares²

Total assets⁴²173.2M DKK in 2021−4% since 2019

Shareholders’ equity⁴²9.3M DKK in 2021−98% since 2017

Cash⁴²102.3M DKK in 2021−84% since 2017

Fiscal year	2017	2018	2019	2020	2021
Cash	631.7M DKK⁴	394.7M DKK²	123.6M DKK²	726.9M DKK²	102.3M DKK²
Current assets					158.9M DKK²
Property, plant and equipment					3.0M DKK²
Intangible assets					2.2M DKK²
Total assets			180.8M DKK⁴	822.5M DKK²	173.2M DKK²
Accounts payable					57.5M DKK²
Short-term debt					31.0M DKK²
Current liabilities					129.1M DKK²
Long-term debt					2.5M DKK²
Long-term liabilities					34.8M DKK²
Retained earnings					-2.1B DKK²
Shareholders’ equity	615.7M DKK⁴	388.2M DKK²	53.0M DKK²	620.5M DKK²	9.3M DKK²

Cash from operations⁴²-602.6M DKK in 2021+157% since 2018

Capital spending⁴²92.0K DKK in 2021−88% since 2018

Free cash flow⁴²-602.7M DKK in 2021+156% since 2018

Fiscal year	2018	2019	2020	2021
Cash from operations	-234.8M DKK⁴	-326.8M DKK²	-539.1M DKK²	-602.6M DKK²
Capital spending	743.0K DKK⁴	2.8M DKK²	2.4M DKK²	92.0K DKK²
Free cash flow	-235.5M DKK	-329.6M DKK	-541.4M DKK	-602.7M DKK
Cash from investing				46.0K DKK²
Cash from financing				-30.3M DKK²

Compare Orphazyme A/S with another company

Corporate structure

Orphazyme A/S sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Orphazyme A/S

Cooperatieve U.a. Lsp V. Filed SC 13G/A on Orphazyme A/S, latest Feb 10, 2023 (2 filings since Feb 3, 2022)

Orphazyme A/S G7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Orphazyme A/S reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	3.0M DKK² Dec 31, 2021	4.7M DKK² Dec 31, 2020	−36.3%
Operating-lease assets (leased space)	5.4M DKK² Dec 31, 2021	14.9M DKK² Dec 31, 2020	−63.4%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	102.3M DKK² Dec 31, 2021	726.9M DKK² Dec 31, 2020	−85.9%

Intangibles and goodwill

Item	Latest	A year before	Change
Intangible assets, net (excluding goodwill)	2.2M DKK² Dec 31, 2021	12.5M DKK² Dec 31, 2020	−82.7%

Filings

53 filings to the SEC since October 2021: 1 annual reports, 2 large holders, 50 other. The latest 20:

Feb 10, 2023SC 13G/A EDGAR
Sep 26, 20226-K EDGAR
Jun 29, 20226-K EDGAR
Jun 28, 202220-F EDGAR
Jun 21, 20226-K EDGAR
Jun 9, 20226-K EDGAR
May 31, 20226-K EDGAR
May 23, 20226-K EDGAR
May 18, 20226-K EDGAR
May 16, 20226-K EDGAR
May 16, 2022NT 20-F/A EDGAR
May 16, 20226-K EDGAR
May 2, 2022NT 20-F EDGAR
Apr 29, 20226-K EDGAR
Apr 29, 20226-K EDGAR
Apr 7, 20226-K EDGAR
Apr 6, 20226-K EDGAR
Apr 6, 20226-K EDGAR
Apr 4, 20226-K EDGAR
Apr 1, 20226-K EDGAR

The 53 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Cooperatieve U.a. Lsp V.SC 13G/A, 2 filings Feb 3, 2022 to Feb 10, 2023⁵

SEC filer profile

How Orphazyme A/S is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGAROrphazyme A/S¹
CIK0001764791
Filer statusNon-accelerated filer<br>emerging growth company¹
Incorporated inDenmark¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
Business addressOle Maaloes Vej 3, Copenhagen N, G7 DK-2200¹
Phone45 39 17 82 72¹
On EDGAR sinceJun 30, 2020¹
Filings107 in all: 6-K (54), CORRESP (9), UPLOAD (6), F-1/A (5), EFFECT (3), FWP (3), SC 13G (3), 20-F (2)¹
All 26 form types
S-8 (2), S-8 POS (2), SC 13G/A (2), SEC STAFF LETTER (2), 15-12B (1), 25 (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), F-1 (1), F-3 (1), NT 20-F (1), NT 20-F/A (1), POS AM (1)
Latest filingsAnnual report (20-F) Jun 28, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAROrphazyme A/S filings on SEC EDGAR
2
SEC EDGAROrphazyme A/S 10-K for fiscal 2021
3
SEC EDGAROrphazyme A/S filings on SEC EDGAR
4
SEC EDGAROrphazyme A/S 10-K for fiscal 2018
5
SEC EDGARCooperatieve U.a. Lsp V. SC 13G/A on Orphazyme A/S